(0.75%) 5 166.15 points
(0.39%) 38 826 points
(0.84%) 16 291 points
(0.22%) $78.28
(2.71%) $2.20
(1.11%) $2 334.30
(3.59%) $27.65
(0.01%) $965.40
(-0.06%) $0.928
(-0.45%) $10.82
(-0.17%) $0.796
(-0.11%) $91.35
Live Chart Being Loaded With Signals
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases...
Stats | |
---|---|
今日成交量 | 15 762.00 |
平均成交量 | 76 692.00 |
市值 | 9.47B |
EPS | €0 ( 2024-02-08 ) |
下一个收益日期 | ( €0 ) 2024-07-23 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | 15.57 |
ATR14 | €0.121 (0.11%) |
音量 相关性
Ipsen SA 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Ipsen SA 相关性 - 货币/商品
Ipsen SA 财务报表
Annual | 2023 |
营收: | €3.13B |
毛利润: | €2.56B (81.74 %) |
EPS: | €7.79 |
FY | 2023 |
营收: | €3.13B |
毛利润: | €2.56B (81.74 %) |
EPS: | €7.79 |
FY | 2023 |
营收: | €0 |
毛利润: | €0 (0.00 %) |
EPS: | €0 |
FY | 2022 |
营收: | €3.03B |
毛利润: | €2.50B (82.56 %) |
EPS: | €7.87 |
Financial Reports:
No articles found.
Ipsen SA
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。